Axogen AXGN
Axogen, Inc. · Nasdaq · Electromedical & Electrotherapeutic Apparatus
Price, last 47 sessions
Our coverage
Nothing published yet.
Insider buying and selling
| Date | Insider | Trade | Shares | Avg. price | Value |
|---|---|---|---|---|---|
| Sept. 2, 2026 | Joseph A. Tyndall director | Sold 10b5-1 plan | 3,500 | $49.70 | $173,940 |
| Aug. 11, 2026 | Amy McBride Wendell director | Sold 10b5-1 plan | 13,353 | $48.42 | $646,592 |
| Aug. 10, 2026 | Marc A. Began EVP & General Counsel | Sold 10b5-1 plan | 67,500 | $47.35 | $3.20 million |
| Aug. 7, 2026 | Kathy Johnson Weiler director | Sold 10b5-1 plan | 14,150 | $45.30 | $640,967 |
Open-market purchases and sales reported on SEC Form 4 filed since July 24, 2026; grants, option exercises and shares withheld for tax aren't shown. A trade under a 10b5-1 plan was scheduled in advance. Where a filing was amended, the amendment's figures are shown.
Recent SEC filings
All 15 →Results of operations and financial condition · Regulation FD disclosure · Financial statements and exhibits
AI summary, unreviewedAxogen Q3 2026 Adjusted EPS of $0.21 Beats $0.13 Consensus on $75.8 Million Revenue; Full-Year Revenue Guidance Raised to At Least $290 Million
Regulation FD disclosure · Financial statements and exhibits
Entry into a material definitive agreement · Regulation FD disclosure · Financial statements and exhibits
Entry into a material definitive agreement · Regulation FD disclosure · Other events · Financial statements and exhibits